Exercise of Options and Issue of Equity

RNS Number : 5174U

e-Therapeutics plc

28 March 2023

 

E-THERAPEUTICS PLC

("e-therapeutics" or the "Company")

EXERCISE OF OPTIONS AND ISSUE OF EQUITY

LONDON, UK, 28 March 2023 - e-therapeutics plc (AIM: ETX), the drug discovery company, announces that it has allotted 500,000 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") following the exercise of share options at 2.8p per New Ordinary Share by a former employee.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur at 8:00 a.m. on or around 11 April 2023. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 582,659,332. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information, please contact:

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO  James Chandler, VP IR & Communications	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc www.etherapeutics.co.uk

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines.  The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic. 

ETX's proprietary Computational Biology Platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery that explicitly considers the true complexity of biology and makes more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data and information resource.  The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence. 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by ETX's Computational Biology Platform.  The focus on hepatocytes offers the opportunity to work across a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health.  ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action. 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates in several therapeutic areas including haematology, cardiovascular disease and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF. 

 

END

 

 

IOEKZGZFDRDGFZM